Literature DB >> 6868109

Measles in Tanzania: antibody response in children after vaccination and antibody state of mothers and newborns.

P W de Haas, N Masurel, W J Anker.   

Abstract

The antibody response to attenuated live measles vaccines was studied in two groups of 29 (A) and 53 (B) African children. In group A 22 sera and in group B 34 sera showed no pre-immunization haemagglutination inhibition (HI) titres. Vaccination resulted in seroconversion in 64 and 85% of groups A and B, respectively. The difference in antibody response between the two groups could be traced to children in the age group seven to eight months, where seroconversion was absent in 67% of group A children and in 0% of group B children. Antibody levels were studied in 234 mothers and their newborns. In 131 serum pairs the antibody levels of mother and child were similar. 78 (33%) of mothers showed a higher titre and 25 (11%) a lower titre than their babies. All newborns except one and all mothers except one possessed antibody titres above 10. Children in the age groups seven to eight months and nine to ten months showed antibody in 12 and 7%, respectively. Over 90% of these children had not been infected in the first ten months of life.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6868109     DOI: 10.1016/0035-9203(83)90086-x

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  2 in total

1.  Immune response to 1 and 2 dose regimens of measles vaccine in Pakistani children.

Authors:  Hamidah Hussain; Dure Samin Akram; Subhash Chandir; Aamir J Khan; Ashraf Memon; Neal A Halsey
Journal:  Hum Vaccin Immunother       Date:  2013-08-08       Impact factor: 3.452

2.  Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis.

Authors:  Sara Carazo; Marie-Noëlle Billard; Amélie Boutin; Gaston De Serres
Journal:  BMC Infect Dis       Date:  2020-03-29       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.